Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 3/20 | 0.41 |
| ▸ | PDE1A | P54750 | 1/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 3/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 9/20 | 0.33 |
| ▸ | PDE8A | O60658 | 2/20 | 0.32 |
| ▸ | PDE5A | O76074 | 2/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.32 |
| ▸ | PDE11A | Q9HCR9 | 2/20 | 0.32 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
| ▸ | PDE9A | O76083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2620420 | 0.91 | PDE1B (0.41) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL2119987 | 0.76 | PDE1B (0.42) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL19522689 | 0.75 | PDE1B (0.43) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL8063327 | 0.73 | PDE1B (0.48) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL3087681 | 0.71 | PDE1B (0.55) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL3000045 | 0.69 | PDE1B (0.60) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL2120812 | 0.68 | PDE1B (0.50) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL8059876 | 0.68 | PDE1B (0.53) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL18349195 | 0.68 | PDE1B (0.50) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL192909 | 0.68 | PDE1B (0.53) | PDE1BPDE1APDE1CPDE2APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094966-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094966-A1 | ORGANIC COMPOUNDS | TPMT, CYP4X1, P2RX4 | PDE1B 4847/4885PDE1A 4868/4885PDE1C 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.